{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":21,"n_cols":5,"rows_kept":21,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[10,2,10,3],[11,2,11,3],[14,2,14,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910484921203321"]
[null,null,"Titolo",null,"Large and medium size vessel and single organ vasculitis / / edited by Carlo Salvarani, Luigi Boiardi, Francesco Muratore"]
[null,null,"Pubbl/distr/stampa",null,"Cham, Switzerland : , : Springer, , [2021]"]
[{"$nulls":4},"©2021"]
[null,null,"ISBN",null,"3-030-67175-5"]
[null,null,"Descrizione fisica",null,"1 online resource (274 pages)"]
[null,null,"Collana",null,"Rare Diseases of the Immune System"]
[null,null,"Disciplina",null,"616.13"]
[null,null,"Soggetti",null,"Vasculitis"]
[{"$nulls":4},"Llibres electrònics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Intro -- Preface -- Contents -- Part I: Giant Cell Arteritis -- 1: Classification Criteria -- References -- 2: Epidemiology and Genetics -- 2.1  Epidemiology -- 2.2  Genetics -- References -- 3: Pathogenesis -- 3.1  Introduction -- 3.2  Model of GCA Pathogenesis -- 3.3  Role of Infectious Agents -- 3.4  Genetics -- 3.5  Immune Effectors of Inflammation in Arteries -- 3.6  Arterial Remodeling -- 3.7  Epigenetics -- 3.8  MicroRNA -- 3.9  Deregulation of the Immune System in Peripheral Blood -- 3.10  Pathways Proven to be Involved in GCA Pathogenesis -- References -- 4: Clinical Manifestations, Differential Diagnosis, and Laboratory Markers -- 4.1  Clinical Manifestations of Giant Cell Arteritis -- 4.2  Differential Diagnosis of Giant Cell Arteritis -- 4.3  Laboratory Markers -- References -- 5: Histopathology and Imaging -- 5.1  Imaging -- 5.2  Temporal Artery Imaging -- 5.3  Large-Vessel Imaging -- References -- 6: Prognosis and Disease Activity -- 6.1  Risk for Complications and Comorbidities During Disease Course -- 6.2  Risk Factors and Biomarkers for Disease Activity in Giant Cell Arteritis -- 6.3  Additional Biomarkers for Assessment of Prognosis-Relevant Comorbidities -- References -- 7: Treatment and Management -- 7.1  General Aspects -- 7.2  Glucocorticoids as First-Line Treatment -- 7.3  Glucocorticoid(GC)-Sparing Agents -- 7.4  Treatment of Comorbidities/Adjuvant Therapies -- References -- Part II: Takayasu Arteritis -- 8: Classification Criteria, Epidemiology and Genetics -- and Pathogenesis -- 8.1  Classification Criteria -- 8.2  Epidemiology and Genetics -- 8.2.1  Incidence and Prevalence -- 8.2.2  Sex -- 8.2.3  Age at Diagnosis -- 8.2.4  Major "]
[{"$nulls":4},"Histocompatibility Complex -- 8.2.5  Non-MHC -- 8.3  Pathogenesis -- References -- 9: Clinical Manifestations, Differential Diagnosis, and Laboratory Markers -- 9.1  Clinical Manifestations."]
[{"$nulls":4},"9.2  Physical Examination -- 9.3  Laboratory: Role of Acute-Phase Response -- 9.4  Differential Diagnosis -- 9.5  Large-Vessel Vasculitis Mimickers in the Differential Diagnosis of TAK -- References -- 10: Imaging -- 10.1  CTA -- 10.2  MRA -- 10.3  FDG-PET -- 10.4  Ultrasonography -- 10.5  Conclusion -- References -- 11: Prognosis and Disease Activity -- 11.1  Disease Activity Assessment -- 11.1.1  Physical Examination in Clinical Activity Assessment -- 11.1.2  Laboratory in Disease Activity Assessment -- 11.1.3  Imaging in Disease Activity Assessment -- 11.1.4  Outcome Measures in Disease Activity Assessment -- 11.2  Prognosis -- 11.2.1  Disease Course -- 11.2.2  Damage Assessment in TAK -- 11.2.3  Mortality -- 11.3  Conclusion -- References -- 12: Treatment -- 12.1  Non-biologic Disease-Modifying Agents -- 12.1.1  Methotrexate -- 12.1.2  Azathioprine -- 12.1.3  Leflunomide -- 12.1.4  Mycophenolate Mofetil -- 12.1.5  Cyclophosphamide -- 12.1.6  Other Non-biologic Disease-Modifying Agents -- 12.2  Biologic Disease-Modifying Agents -- 12.2.1  Tumor Necrosis Factor Inhibitors -- 12.2.2  Tociluzumab -- 12.2.3  Rituximab -- 12.2.4  Other Biologic Disease-Modifying Agents -- 12.3  Vascular Interventions and Surgical Therapy -- 12.4  Conclusion -- References -- Part III: Polyarteritis Nodosa -- 13: Cutaneous Polyarteritis Nodosa -- 13.1  Introduction -- 13.2  Epidemiology, Genetics, Pathogenesis -- 13.3  Clinical Manifestations and Laboratory Markers -- 13.3.1  Clinical Manifestations -- 13.3.2  Laboratory Markers -- 13.4  Histopathology -- 13.5  Diagnosis and Differential Diagnosis -- 13.6  Treatment -- 13.7  Prognosis and Disease Activity -- References -- 14: Systemic Polyarteritis Nodosa -- 14.1  Introduction -- 14.2  Epidemiology -- 14.3  Etiopathogenesis -- 14.4  Clinical Manifestations and Laboratory Markers -- 14.4.1  Clinical Manifestations."]
[{"$nulls":4},"14.4.2  Laboratory Markers -- 14.5  Histopathology -- 14.6  Diagnosis and Differential Diagnosis -- 14.7  Prognosis -- 14.8  Treatment -- References -- Part IV: Single Organ Vasculitis -- 15: Adult Primary Central Nervous System Vasculitis -- 15.1  Introduction -- 15.2  Diagnosis and Diagnostic Criteria -- 15.3  Histopathology -- 15.4  Clinical Manifestations and Laboratory Findings -- 15.5  PCNSV Subsets -- 15.6  Differential Diagnosis -- 15.7  Treatment -- 15.7.1  Mayo Clinic Cohort of Patients with Adult PCNSV -- 15.7.2  French Cohort of Patients with Primary Central Nervous System Vasculitis -- 15.7.3  Monitoring Disease Course -- References -- 16: Isolated Aortitis and Periaortitis -- 16.1  Introduction -- 16.2  Clinical Features and Diagnosis -- 16.2.1  Isolated Aortitis -- 16.2.2  Periaortitis -- 16.2.3  IgG4-Related Aortitis and Periaortitis -- 16.3  Treatment -- 16.4  Conclusions -- References -- 17: Isolated Gastrointestinal Vasculitis -- 17.1  Introduction -- 17.2  Epidemiology -- 17.3  Clinical Manifestations -- 17.4  Diagnosis -- 17.5  Differential Diagnosis -- 17.6  Management -- 17.7  Prognosis -- References -- 18: Cutaneous Vasculitis -- 18.1  Introduction -- 18.2  Nomenclature and Classification of Cutaneous Vasculitis -- 18.3  Clinical Spectrum of Cutaneous Vasculitis -- 18.4  Cutaneous Vasculitic Manifestations in Systemic Vasculitides with Predominant Organ Involvement Different from the Skin -- 18.4.1  Polyarteritis Nodosa -- 18.4.2  Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis -- 18.4.2.1  MPA -- 18.4.2.2  GPA -- 18.4.2.3  EGPA -- 18.4.3  Immune Complex Small-Vessel Vasculitis -- 18.4.3.1  IgA Vasculitis (IgAV) -- 18.4.3.2  Cryoglobulinemic Vasculitis -- 18.4.3.3  Urticarial Vasculitis "]
[{"$nulls":4},"-- 18.5  Cutaneous Vasculitis Associated with Autoimmune Systemic Diseases -- 18.5.1  Rheumatoid Arthritis (RA)."]
[{"$nulls":4},"18.5.2  Systemic Lupus Erythematous (SLE) -- 18.5.3  Primary Sjögren Syndrome (PSS) -- 18.6  Cutaneous Single-Organ Vasculitis (SOV) -- 18.6.1  Erythema Elevatum et Diutinum (EED) -- 18.6.2  Nodular Vasculitis (Erythema Induratum of Bazin) -- 18.6.3  Hypergammaglobulinemic Macular Vasculitis (Hypergammaglobulinemic Purpura of Waldenström) -- 18.7  Diagnostic Approach in a Patient Presenting with Cutaneous Vasculitis -- 18.8  Treatment of Cutaneous Vasculitis -- References -- 19: Single-Organ Genitourinary Vasculitis -- 19.1  Introduction -- 19.2  Gynecologic Single-Organ Vasculitis -- 19.3  Male Genital Tract Single-Organ Vasculitis -- 19.3.1  Testicles, Epididymis, and Spermatic Cords -- 19.3.2  Prostate, Seminal Vesicles, and Penis -- 19.4  Urinary Tract Single-Organ Vasculitis -- 19.4.1  Ureters -- 19.4.2  Urinary Bladder -- 19.4.3  Urethra -- 19.5  Conclusions -- References -- Part V: Arterial and Venous Involvement in Behçet's Disease -- 20: Arterial and Venous Involvement in Behçet's Disease -- 20.1  Epidemiology -- 20.2  Pathology -- 20.3  Pathophysiology -- 20.4  Clinical Features and Prognosis of Venous Involvement -- 20.4.1  Deep Vein Thrombosis of Lower Extremities -- 20.4.2  Venous Wall Thickness in Behçet's Disease -- 20.4.3  Thrombosis of Superior and Inferior Vena Cava -- 20.4.4  Budd-Chiari Syndrome -- 20.4.5  Cerebral Sinus Thrombosis -- 20.5  Clinical Features and Prognosis of Arterial Involvement -- 20.5.1  Pulmonary Arterial Involvement -- 20.5.2  Peripheral Arterial Involvement -- 20.5.3  Cardiac Involvement -- 20.6  Imaging in Vascular Involvement of Behçet's Disease -- 20.7  Diagnosis -- 20.8  Treatment -- 20.8.1  Medical Treatment -- 20.9  Anticoagulation -- 20.10  Surgical Treatment -- 20.11  Conclusion -- References -- Correction to: Isolated Gastrointestinal Vasculitis."]
[{"$nulls":4},"Correction to: C. Salvarani et al. (eds.), Large and Medium Size Vessel and Single Organ Vasculitis, Rare Diseases of the Immune System, https://doi.org/10.1007/978-3-030-67175-4_17 -- Index."]